Zoledronic acid cost effective in preventing AI-associated bone loss

Author：

ISSN： 1173-5503

Source： PharmacoEconomics and Outcomes News, Vol.1, Iss.564, 2008-01, pp. : 1-1

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Zoledronic acid a fast fix for AI-induced bone loss

Inpharma, Vol. 1, Iss. 1620, 2008-01 ,pp. : 7-8

Adis International

Access to resources Recommend Favorite

Zoledronic acid to prevent SREs in prostate, renal cancer cost effective

PharmacoEconomics and Outcomes News, Vol. 1, Iss. 578, 2009-01 ,pp. : 9-9

Adis International

Access to resources Recommend Favorite

Risedronic acid prevents bone loss in postmenopausal women with breast cancer, with or without aromatase inhibitor (AI) therapy,

Inpharma, Vol. 1, Iss. 1637, 2008-01 ,pp. : 18-18

Adis International

Access to resources Recommend Favorite

No bones about the cost effectiveness of zoledronic acid

Inpharma, Vol. 1, Iss. 1613, 2007-01 ,pp. : 13-14

Adis International

Access to resources Recommend Favorite

No bones about the cost effectiveness of zoledronic acid

PharmacoEconomics and Outcomes News, Vol. 1, Iss. 541, 2007-01 ,pp. : 11-12

Adis International

Access to resources Recommend Favorite